Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance]
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Yahoo! Finance
Several biotech firms have set targets to purchase up to 1 million bitcoin, citing its appeal as a hedge against inflation and economic uncertainty. While some critics argue that bitcoin's volatility makes it unfit as an inflation hedge, others see it as a legitimate tool for corporate treasurers. Companies are exploring ways to monetize their bitcoin holdings without selling them, such as using them as collateral to secure loans. By Niket Nishant and Bhanvi Satija (Reuters) - U.S. President-elect Donald Trump's pro-crypto stance is prompting small businesses to allocate portions of their cash to bitcoin, challenging the dominance of traditional assets as companies look for more robust inflation hedges. Over the past month, biotech firms Enlivex Therapeutics, Acurx Pharmaceuticals and Hoth Therapeutics have set a target of purchasing up to $1 million of bitcoin to hold as a treasury reserve asset. The moves underscore the growing appeal of bitcoin as a legitimate tool for corp
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.MarketBeat
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]Yahoo! Finance
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisGlobeNewswire
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
ENLV
Analyst Actions
- 9/27/24 - HC Wainwright
ENLV
Sec Filings
- 12/11/24 - Form 6-K
- 12/3/24 - Form 6-K
- 11/29/24 - Form 6-K
- ENLV's page on the SEC website